MM-111-13-02-04) Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients with `"Traditional" and "Non-Traditional" HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

The primary objective of the study is to compare the patient Progression Free Survival (PFS) between the experimental and comparator arms within two distinct patient populations. Patients with "Traditional" and "Non Traditional" HER2 expressing tumors.

Study Number: 

PH 232012

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail